Takeda Pharmaceutical Company Limited Share Price
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,269.00 JPY | -0.32% |
|
-8.27% | +8.98% |
| 12:05am | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
| 08-05 | US FDA approves Takeda's sleep disorder pill | RE |
| Market Cap | 8,413B 53.34B 46.18B 43.06B 39.63B 74.74B 5,072B 75.63B 502B 198B 2,542B 200B 196B | P/E 2027 * |
42.3x | P/E 2028 * | 26.2x |
|---|---|---|---|---|---|
| Enterprise Value | 12,346B 78.27B 67.77B 63.19B 58.15B 110B 7,442B 111B 737B 290B 3,730B 294B 288B | EV / Sales 2027 * |
2.64x | EV / Sales 2028 * | 2.57x |
| Free-Float |
99.28% | Yield 2027 * |
3.88% | Yield 2028 * | 3.97% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | -0.32% | ||
| 1 week | -8.27% | ||
| Current month | -4.43% | ||
| 1 month | -1.68% | ||
| 3 months | +0.57% | ||
| 6 months | -3.99% | ||
| Current year | +8.98% |
| 1 week | 5,225 |  | 5,820 |
| 1 month | 5,225 | | 5,903 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 23/06/2026 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 31/12/2018 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 31/05/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% | ||
| 10/07/26 | Issuer sale | President, Japan Pharma B.U. | -1,022 | 0.0001% | ||
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | -8.27% | +24.89% | +21.29% | 53.57B | |
| +4.86% | -4.16% | +52.13% | +160.26% | 995B | |
| +1.04% | -3.43% | +50.60% | +52.38% | 614B | |
| +0.98% | -6.46% | +24.85% | +66.66% | 431B | |
| +1.96% | -0.87% | +43.02% | +37.60% | 353B | |
| -0.11% | -4.56% | +31.59% | +39.73% | 293B | |
| +2.52% | -6.99% | +8.08% | +10.32% | 245B | |
| +4.57% | +3.75% | +35.07% | +67.64% | 210B | |
| -4.32% | -12.25% | -5.97% | -44.56% | 210B | |
| -2.58% | -1.91% | +15.06% | +67.46% | 168B | |
| Average | +0.68% | -5.31% | +27.93% | +47.88% | 357.18B | |
| Weighted average by Cap. | +0.61% | -5.92% | +36.41% | +74.23% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,668B 29.6B 25.62B 23.89B 21.99B 41.47B 2,814B 41.96B 279B 110B 1,410B 111B 109B | 4,747B 30.09B 26.05B 24.29B 22.36B 42.16B 2,861B 42.67B 283B 112B 1,434B 113B 111B |
| Net income | 191B 1.21B 1.05B 975M 898M 1.69B 115B 1.71B 11.37B 4.48B 57.58B 4.54B 4.44B | 316B 2B 1.74B 1.62B 1.49B 2.81B 191B 2.84B 18.86B 7.44B 95.5B 7.53B 7.36B |
| Net Debt | 3,932B 24.93B 21.58B 20.13B 18.52B 34.93B 2,370B 35.35B 235B 92.53B 1,188B 93.66B 91.6B | 3,779B 23.96B 20.74B 19.34B 17.8B 33.56B 2,278B 33.97B 225B 88.91B 1,141B 90B 88.02B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/08/26 | JP¥5,269.00 | -0.32% | 3,470,800 |
| 04/08/26 | JP¥5,286.00 | -2.26% | 3,851,800 |
| 03/08/26 | JP¥5,408.00 | -1.90% | 4,750,600 |
| 31/07/26 | JP¥5,513.00 | -3.59% | 7,218,600 |
| 30/07/26 | JP¥5,718.00 | -2.21% | 4,859,800 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
